Silencing of the glycerophosphocholine phosphodiesterase GDPD5 alters the phospholipid metabolite profile in a breast cancer model in vivo as monitored by 31P MRS

J. P. Wijnen; L. Jiang; T. R. Greenwood; M. Cheng; M. Döpkens; M. D. Cao; Z. M. Bhujwalla; B. Krishnamachary; D. W.J. Klomp; K. Glunde

doi:10.1002/nbm.3106

Silencing of the glycerophosphocholine phosphodiesterase GDPD5 alters the phospholipid metabolite profile in a breast cancer model in vivo as monitored by ³¹P MRS

J. P. Wijnen, L. Jiang, T. R. Greenwood, M. Cheng, M. Döpkens, M. D. Cao, Z. M. Bhujwalla, B. Krishnamachary, D. W.J. Klomp, K. Glunde

School of Medicine

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

Abnormal choline phospholipid metabolism is an emerging hallmark of cancer, which is implicated in carcinogenesis and tumor progression. The malignant metabolic phenotype is characterized by high levels of phosphocholine (PC) and relatively low levels of glycerophosphocholine (GPC) in aggressive breast cancer cells. Phosphorus (³¹P) MRS is able to non-invasively detect these water-soluble metabolites of choline as well as ethanolamine phospholipid metabolism. Here we have investigated the effects of stably silencing glycerophosphoester diesterase domain containing 5 (GDPD5), which is an enzyme with glycerophosphocholine phosphodiesterase activity, in MDA-MB-231 breast cancer cells and orthotopic tumor xenografts. Tumors in which GDPD5 was stably silenced with GDPD5-specific shRNA contained increased levels of GPC and phosphoethanolamine (PE) compared with control tumors.

Original language	English (US)
Pages (from-to)	692-699
Number of pages	8
Journal	NMR in biomedicine
Volume	27
Issue number	6
DOIs	https://doi.org/10.1002/nbm.3106
State	Published - Jun 2014

Keywords

Breast cancer
GDPD5
Glycerophosphoesterdiesterase
In vivo
Metabolism
Silencing

ASJC Scopus subject areas

Molecular Medicine
Radiology Nuclear Medicine and imaging
Spectroscopy

Access to Document

10.1002/nbm.3106

Cite this

Wijnen, J. P., Jiang, L., Greenwood, T. R., Cheng, M., Döpkens, M., Cao, M. D., Bhujwalla, Z. M., Krishnamachary, B., Klomp, D. W. J., & Glunde, K. (2014). Silencing of the glycerophosphocholine phosphodiesterase GDPD5 alters the phospholipid metabolite profile in a breast cancer model in vivo as monitored by ³¹P MRS. NMR in biomedicine, 27(6), 692-699. https://doi.org/10.1002/nbm.3106

Wijnen, JP, Jiang, L, Greenwood, TR, Cheng, M, Döpkens, M, Cao, MD, Bhujwalla, ZM , Krishnamachary, B, Klomp, DWJ & Glunde, K 2014, 'Silencing of the glycerophosphocholine phosphodiesterase GDPD5 alters the phospholipid metabolite profile in a breast cancer model in vivo as monitored by ³¹P MRS', NMR in biomedicine, vol. 27, no. 6, pp. 692-699. https://doi.org/10.1002/nbm.3106

@article{7f53e8c1954b46aba6aee86eba011317,

title = "Silencing of the glycerophosphocholine phosphodiesterase GDPD5 alters the phospholipid metabolite profile in a breast cancer model in vivo as monitored by 31P MRS",

abstract = "Abnormal choline phospholipid metabolism is an emerging hallmark of cancer, which is implicated in carcinogenesis and tumor progression. The malignant metabolic phenotype is characterized by high levels of phosphocholine (PC) and relatively low levels of glycerophosphocholine (GPC) in aggressive breast cancer cells. Phosphorus (31P) MRS is able to non-invasively detect these water-soluble metabolites of choline as well as ethanolamine phospholipid metabolism. Here we have investigated the effects of stably silencing glycerophosphoester diesterase domain containing 5 (GDPD5), which is an enzyme with glycerophosphocholine phosphodiesterase activity, in MDA-MB-231 breast cancer cells and orthotopic tumor xenografts. Tumors in which GDPD5 was stably silenced with GDPD5-specific shRNA contained increased levels of GPC and phosphoethanolamine (PE) compared with control tumors.",

keywords = "Breast cancer, GDPD5, Glycerophosphoesterdiesterase, In vivo, Metabolism, Silencing",

author = "Wijnen, {J. P.} and L. Jiang and Greenwood, {T. R.} and M. Cheng and M. D{\"o}pkens and Cao, {M. D.} and Bhujwalla, {Z. M.} and B. Krishnamachary and Klomp, {D. W.J.} and K. Glunde",

year = "2014",

month = jun,

doi = "10.1002/nbm.3106",

language = "English (US)",

volume = "27",

pages = "692--699",

journal = "NMR in biomedicine",

issn = "0952-3480",

publisher = "John Wiley and Sons Ltd",

number = "6",

}

TY - JOUR

T1 - Silencing of the glycerophosphocholine phosphodiesterase GDPD5 alters the phospholipid metabolite profile in a breast cancer model in vivo as monitored by 31P MRS

AU - Wijnen, J. P.

AU - Jiang, L.

AU - Greenwood, T. R.

AU - Cheng, M.

AU - Döpkens, M.

AU - Cao, M. D.

AU - Bhujwalla, Z. M.

AU - Krishnamachary, B.

AU - Klomp, D. W.J.

AU - Glunde, K.

PY - 2014/6

Y1 - 2014/6

N2 - Abnormal choline phospholipid metabolism is an emerging hallmark of cancer, which is implicated in carcinogenesis and tumor progression. The malignant metabolic phenotype is characterized by high levels of phosphocholine (PC) and relatively low levels of glycerophosphocholine (GPC) in aggressive breast cancer cells. Phosphorus (31P) MRS is able to non-invasively detect these water-soluble metabolites of choline as well as ethanolamine phospholipid metabolism. Here we have investigated the effects of stably silencing glycerophosphoester diesterase domain containing 5 (GDPD5), which is an enzyme with glycerophosphocholine phosphodiesterase activity, in MDA-MB-231 breast cancer cells and orthotopic tumor xenografts. Tumors in which GDPD5 was stably silenced with GDPD5-specific shRNA contained increased levels of GPC and phosphoethanolamine (PE) compared with control tumors.

AB - Abnormal choline phospholipid metabolism is an emerging hallmark of cancer, which is implicated in carcinogenesis and tumor progression. The malignant metabolic phenotype is characterized by high levels of phosphocholine (PC) and relatively low levels of glycerophosphocholine (GPC) in aggressive breast cancer cells. Phosphorus (31P) MRS is able to non-invasively detect these water-soluble metabolites of choline as well as ethanolamine phospholipid metabolism. Here we have investigated the effects of stably silencing glycerophosphoester diesterase domain containing 5 (GDPD5), which is an enzyme with glycerophosphocholine phosphodiesterase activity, in MDA-MB-231 breast cancer cells and orthotopic tumor xenografts. Tumors in which GDPD5 was stably silenced with GDPD5-specific shRNA contained increased levels of GPC and phosphoethanolamine (PE) compared with control tumors.

KW - Breast cancer

KW - GDPD5

KW - Glycerophosphoesterdiesterase

KW - In vivo

KW - Metabolism

KW - Silencing

UR - http://www.scopus.com/inward/record.url?scp=84899913524&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899913524&partnerID=8YFLogxK

U2 - 10.1002/nbm.3106

DO - 10.1002/nbm.3106

M3 - Article

C2 - 24764256

AN - SCOPUS:84899913524

SN - 0952-3480

VL - 27

SP - 692

EP - 699

JO - NMR in biomedicine

JF - NMR in biomedicine

IS - 6

ER -